Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atropine-edrophonium mixture: a dose-response study.

M Naguib1, M Gomaa, G H Absood

  • 1Department of Anesthesiology, King Faisal University, King Fahd Hospital, Al Khobar, Saudi Arabia.

Anesthesia and Analgesia
|July 1, 1988
PubMed
Summary

Higher doses of atropine are needed to prevent bradycardia when combined with a larger dose of edrophonium after pancuronium blockade. This study determined effective atropine doses for preventing bradycardia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Numerical simulation and design recommendations for prestressed steel stayed columns subjected to static and dynamic effects.

Scientific reports·2025
Same author

Applying of SP, DC-Resistivity, DC-TDIP and TDEM soundings in high saline coastal aquifer.

Heliyon·2021
Same author

Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients.

Journal of advanced research·2020
Same author

Neostigmine-induced weakness after sugammadex - a reply.

Anaesthesia·2019
Same author

Neostigmine-induced weakness: what are the facts?

Anaesthesia·2018
Same author

Sugammadex-induced bradycardia and asystole: how great is the risk?

British journal of anaesthesia·2018

Area of Science:

  • Anesthesiology
  • Pharmacology

Background:

  • Neuromuscular blockade reversal is critical in anesthesia.
  • Bradycardia is a potential complication during reversal.
  • Atropine is commonly used to counteract bradycardia.

Purpose of the Study:

  • To determine the dose-response of atropine for preventing bradycardia.
  • To establish the effective dose 50 (ED50) and effective dose 95 (ED95) of atropine.
  • To compare atropine requirements when combined with different edrophonium doses after pancuronium blockade.

Main Methods:

  • Seventy-two patients undergoing pancuronium blockade received edrophonium-atropine mixtures.
  • Two groups received different edrophonium doses (0.67 mg/kg or 1.0 mg/kg) mixed with varying atropine doses.
  • Dose-response curves for atropine were constructed at 5 and 10 minutes post-injection.

Related Experiment Videos

Main Results:

  • Dose-response curves for atropine were parallel in both groups.
  • Higher atropine doses (1.6-2 times greater) were required in the group receiving a higher edrophonium dose.
  • Specific ED50 and ED95 values for atropine were estimated at 5 and 10 minutes.

Conclusions:

  • The dose of edrophonium influences the required dose of atropine for bradycardia prevention.
  • Understanding these dose-response relationships is crucial for safe anesthetic practice.
  • Optimized atropine dosing can mitigate bradycardia during neuromuscular blockade reversal.